greeksoup/ stock research
Stock research / United States / JNJ · Pharmaceutical Preparations · NYSE

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company whose operating companies do business in virtually all countries of the world, with approximately 138,200 employees engaged in the research and development, manufacture and sale of healthcare products. Its primary focus is products related to human health and well-being. It was incorporated in New Jersey in 1887. The company is organised into two business segments: one it calls Innovative Medicine, the prescription medicines, and one it calls MedTech, the devices and equipment used in procedures.

Johnson & Johnson

Johnson & Johnson is a holding company whose operating companies do business in virtually all countries of the world, with approximately 138,200 employees engaged in the research and development, manufacture and sale of healthcare products. Its primary focus is products related to human health and well-being. It was incorporated in New Jersey in 1887. The company is organised into two business segments: one it calls Innovative Medicine, the prescription medicines, and one it calls MedTech, the devices and equipment used in procedures.

Innovative Medicine

Six therapeutic areas: oncology, covering prostate cancer, hematologic malignancies, lung cancer and bladder cancer; immunology, covering rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; neuroscience, covering mood disorders, neurodegenerative disorders and schizophrenia; pulmonary hypertension; infectious diseases, including HIV and AIDS; and cardiovascular and metabolism, covering thrombosis, diabetes and macular degeneration. The medicines are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

In oncology the named products include DARZALEX and DARZALEX FASPRO for multiple myeloma, the latter also for light chain amyloidosis; CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma; TALVEY and TECVAYLI, bispecific antibodies for multiple myeloma after at least four prior lines of therapy; ERLEADA and ZYTIGA for prostate cancer; IMBRUVICA for certain B-cell malignancies and chronic graft versus host disease; and RYBREVANT with LAZCLUZE, plus the subcutaneous RYBREVANT FASPRO, for EGFR-mutated non-small cell lung cancer.

In immunology they include STELARA and TREMFYA, both spanning plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis; REMICADE for immune-mediated inflammatory diseases; and SIMPONI and SIMPONI ARIA, the subcutaneous and intravenous forms of golimumab. In neuroscience they include CAPLYTA for major depressive disorder, bipolar depression and schizophrenia; INVEGA SUSTENNA and INVEGA TRINZA, sold as XEPLION and TREVICTA in some markets, for schizophrenia; SPRAVATO, a nasal spray for treatment-resistant depression; and CONCERTA for attention deficit hyperactivity disorder. The HIV medicines are EDURANT, PREZISTA, PREZCOBIX, also sold as REZOLSTA, and the single-tablet regimen SYMTUZA. Pulmonary arterial hypertension is served by OPSUMIT and OPSYNVI and by UPTRAVI, which the filing describes as the only approved oral and intravenous selective IP receptor agonist targeting a prostacyclin pathway in that disease. XARELTO is the oral anticoagulant, used after hip or knee replacement, in nonvalvular atrial fibrillation, in coronary and peripheral artery disease and in children. Many of these medicines were developed with strategic partners or licensed from other companies.

MedTech

Products used in cardiovascular, orthopaedic, surgical and vision procedures, sold to physicians, hospitals, eye care professionals and healthcare systems for acute and elective work, and aimed at disease states where the procedure itself is central to the outcome.

The cardiovascular portfolio covers electrophysiology products for diagnosing and treating heart rhythm disorders, the Abiomed mechanical circulatory support technologies used in cardiogenic shock and high-risk percutaneous coronary intervention, the Shockwave circulatory restoration products for calcified coronary and peripheral artery disease, and neurovascular care treating stroke, all delivered mainly through minimally invasive catheter-based approaches. Orthopaedics covers joint reconstruction, trauma, spine and sports injuries. Surgery covers open, laparoscopic and robotic procedures, with instrumentation, energy devices, stapling systems, wound closure, biosurgery products and digital and robotic technologies, and includes the Mentor breast aesthetics and reconstruction products. Vision covers ACUVUE contact lenses, TECNIS premium intraocular lenses for cataract surgery, and other cataract and refractive products. MedTech products are distributed to wholesalers, hospitals and retailers.

The Orthopaedics separation

In October 2025 the company announced its intention to separate the Orthopaedics business. The filing states that it intends to explore multiple paths to effect the planned separation, with a targeted completion within 18 to 24 months of the initial announcement.

From Johnson & Johnson's annual report on Form 10-K for the year ended 28 December 2025. The filing

Compare with another name What $10,000 in Johnson & Johnson became

Latest results

Latest quarterQ3 FY2026ended 27 September 2026 · 10-Q filed 21 October 2026
Revenue
$25.4 billion
+5.9% on the year · +0.4% on the quarter
Q4 FY2024Q3 FY2026
Net income
$210 million
-95.9% on the year · -96.2% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$0.09
-95.8% on the year · -96.0% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 28 December 2025 · 10-K filed 11 February 2026
Revenue
$94.2 billion
+6.0% on the year
FY2018FY2025
Net income
$26.8 billion
+90.6% on the year
FY2018FY2025
Diluted EPS
$11.03
+90.5% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsJohnson & Johnson (JNJ) reported revenue of $94.2 billion for fiscal 2025, the year ended 28 December 2025, up 6.0% on the year before. Net income was $26.8 billion and diluted earnings per share $11.03. Revenue was $88.8 billion in fiscal 2024, $85.2 billion in fiscal 2023, $80.0 billion in fiscal 2022 and $78.7 billion in fiscal 2021. Net income in the same years was $14.1 billion, $35.2 billion, $17.9 billion and $20.9 billion. Over the twelve months to 27 September 2026, Johnson & Johnson reported revenue of $99.3 billion and net income of $16.1 billion. Revenue grew 2.7% a year, compounded, over the five years to fiscal 2025. Johnson & Johnson declared $5.28 a share in dividends over the last four quarters and had 2.41 billion shares outstanding at the latest filed count. At 27 September 2026 it carried $44.7 billion of debt and $16.9 billion of cash. At the close of 6 November 2026 the market cap of Johnson & Johnson was $665.0 billion, 41.9 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE19.7%
ROCEn/a
Operating marginn/a
Net margin16.2%
FCF margin20.7%
Interest covern/a
Debt to equity0.55x
Cash conversion1.63x
Share count, last 12 months-0.1%
Sales CAGR, 3 years5.6%
Profit CAGR, 3 years14.3%
EPS, TTM$6.60

At the close of 6 November 2026

Price$276.25
Market cap$665.0 billion
Stock P/E41.9x
Price to book8.2x
EV / EBITDAn/a
Dividend yield1.9%
Market cap / sales6.7x
52-week high$278.43
52-week low$186.57
Price, 1 year47.8%
Price CAGR, 3 years22.3%
Price CAGR, 5 years11.1%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Johnson & Johnson's balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
JNJgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022 †Q2 FY2022 †Q3 FY2022 †Q4 FY2022Q1 FY2023 †Q2 FY2023 †Q3 FY2023Q4 FY2023 †Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue24,80419,84020,21519,99619,93920,89421,51921,35121,39521,38322,44722,47122,52021,89323,74323,99324,56424,06225,31025,399
Cost of revenue7,9557,5987,9196,1727,7656,6876,4626,6066,7986,5116,8696,9637,1287,3577,6287,3037,9688,1068,0518,097
Gross profit16,84913,82213,89313,82413,85514,20715,05714,74514,59714,87215,57815,50815,39214,53616,11516,69016,59615,95617,25917,302
Gross margin68%70%69%69%69%68%70%69%68%70%69%69%68%66%68%70%68%66%68%68%
R&D4,7203,4623,7033,4853,8413,4553,7033,4474,2463,5423,4404,9525,2983,2253,5163,6724,2523,5273,6534,652
SG&A7,1545,9386,2264,9756,5124,9065,3965,4005,8105,2575,6815,4786,4535,1125,8895,9226,7536,0346,4326,285
Interest expense60.010.038.051.017721234619219.0155270193137204308245214272281217
Pre-tax income4,8365,2035,1445,1723,840-1,2876,3065,2174,8263,7145,7483,3383,88713,6316,4917,4934,9665,9906,74734.0
Tax rate2%14%20%17%18%n/a15%17%14%12%18%19%12%19%15%31%-3%13%18%-518%
Net income4,7365,1494,8144,4583,520-68.05,14426,0284,0493,2554,6862,6943,43110,9995,5375,1525,1165,2355,534210
Net margin19%26%24%22%18%-0%24%122%19%15%21%12%15%50%23%21%21%22%22%1%
Diluted EPS$1.77$1.93$1.80$1.68$1.33-$0.03$1.96$10.21$1.67$1.34$1.93$1.11$1.41$4.54$2.29$2.12$2.10$2.14$2.27$0.09
Operating cash flow5,7323,9795,5816,2845,3503,2574,1827,4897,8633,6575,6337,9936,9834,1743,8789,1697,3092,5148,6167,720
Capital expenditure1,4156078639521,5878631,1249671,5898079761,0291,6127951,0431,1571,8371,0491,3211,362
Free cash flow4,3173,3724,7185,3323,7632,3943,0586,5226,2742,8504,6576,9645,3713,3792,8358,0125,4721,4657,2956,358
Buybacks9961,5779732,1651,3203,5373819202161,4751365392822,1270.01,9021,9244,0282211,709
Dividends paid2,7912,7872,9712,9702,9542,9423,0922,8712,8652,8692,9852,9852,9842,9893,1293,1323,1313,1313,2273,227
Shares outstanding2,629m2,631m2,629m2,614m2,409m2,599m2,599m2,407m2,409m2,407m2,407m2,408m2,408m2,406m2,408m2,409m2,410m2,407m2,410m2,407m
Filing10-K10-K10-K10-Q10-K10-K10-K10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008FY2009FY2010FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020FY2021 †FY2022 †FY2023FY2024FY2025TTM
Revenue61,09563,74761,89761,58765,03067,22471,31274,33170,07471,89076,45081,58182,05982,58478,74079,99085,15988,82194,19399,335
Cost of revenue17,75118,51118,44718,79220,36021,65822,34222,74621,53621,78925,43927,09127,55628,42723,40224,59626,55327,47130,25632,222
Gross profit43,34445,23643,45042,79544,67045,56648,97051,58548,53850,10151,09654,49054,50354,15755,33855,39458,60661,35063,93767,113
Gross margin70.9%71.0%70.2%69.5%68.7%67.8%68.7%69.4%69.3%69.7%66.8%66.8%66.4%65.6%70.3%69.3%68.8%69.1%67.9%67.6%
Research and development7,6807,5776,9866,8447,5487,6658,1838,4949,0469,14310,59410,77511,35512,1590.00.04831,84110916,084
Selling, general and administrative20,45121,49019,80119,42420,96920,86921,83021,95421,20320,06721,52022,54022,17822,08420,11820,24621,51222,86923,67625,504
Operating incomen/an/a16,58217,70013,76514,95516,41221,590n/an/an/an/an/an/an/an/an/an/an/an/a
Operating marginn/an/a26.8%28.7%21.2%22.2%23.0%29.0%n/an/an/an/an/an/an/an/an/an/an/an/a
Interest expense2964354514555715324825335527269341,005318201183276772755971984
Pre-tax income13,28316,92915,75516,94712,36113,77515,47120,56319,19619,80317,67317,99917,32816,49719,17819,35915,06216,68732,58117,737
Income tax2,7073,9803,4893,6132,6893,2611,6404,2403,7873,26316,3732,7022,2091,7831,3772,9891,7362,6215,7771,642
Effective tax rate20.4%23.5%22.1%21.3%21.8%23.7%10.6%20.6%19.7%16.5%92.6%15.0%12.7%10.8%7.2%15.4%11.5%15.7%17.7%9.3%
Net income10,57612,94912,26613,3349,67210,85313,83116,32315,40916,5401,30015,29715,11914,71420,87817,94135,15314,06626,80416,095
Net margin17.3%20.3%19.8%21.7%14.9%16.1%19.4%22.0%22.0%23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%16.2%
Diluted EPS$3.63$4.57$4.40$4.78$3.49$3.86$4.81$5.70$5.48$5.93$0.47$5.61$5.63$5.51$7.81$6.73$13.72$5.79$11.03$6.60
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2012 to FY2025

FY2012FY2012FY2013FY2014FY2016FY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025Share
of the parts, latest year
Innovative Medicinen/an/an/an/an/an/an/an/an/an/a51,68052,56354,75956,96460,40164.1%
MedTechn/an/an/an/an/an/an/an/an/a22,95927,06027,42730,40031,85733,79235.9%
Consumer Health14,88314,44714,69714,49613,50713,30713,60213,85313,89814,450n/an/an/an/an/an/a
Medical Devices25,77927,42628,49027,52225,13725,11926,59226,99425,963n/an/an/an/an/an/an/a
Pharmaceutical24,36825,35128,12532,31331,43033,46436,25640,73442,19845,175n/an/an/an/an/an/a
Innovative Medicine FY2022 to FY2025MedTech FY2021 to FY2025Pharmaceutical FY2012 to FY2021Consumer Health FY2012 to FY2021Medical Devices FY2012 to FY2019
65.0FY201271.3FY201370.1FY201676.5FY201782.1FY201978.7FY202285.2FY202394.2FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Profit by segment FY2013 to FY2025

The profit before tax each segment reports. Costs Johnson & Johnson does not charge to a segment are left out, so the segments can add up to more than the company's own profit before tax.

FY2013FY2014FY2016FY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025Margin
FY2025
Innovative Medicinen/an/an/an/an/an/an/an/a17,75015,64718,24618,91922,26636.9%
MedTechn/an/an/an/an/an/an/a3,0444,2084,4474,6693,7404,11312.2%
Consumer Health1,9731,9411,7872,4412,5242,3202,061-852n/an/an/an/an/an/a
Medical Devices5,2617,9536,8265,5785,3924,3977,286n/an/an/an/an/an/an/a
Pharmaceutical9,17811,69611,73412,82711,08312,5688,81615,250n/an/an/an/an/an/a
Innovative Medicine FY2022 to FY2025Pharmaceutical FY2013 to FY2021MedTech FY2021 to FY2025Medical Devices FY2013 to FY2019Consumer Health FY2013 to FY2021
16.4FY201320.3FY201619.0FY201718.2FY201922.0FY202222.9FY202326.4FY2025

$ billion; the figure over a bar is all the segments together; a year a segment lost money, it hangs below the line. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
Innovative Medicine64%84%
MedTech36%16%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has a profit before tax figure. A margin is a segment's profit before tax over its own sales.

Revenue by region FY2017 to FY2025

FY2017FY2017FY2018FY2019FY2021FY2022FY2023FY2023FY2024FY2025Share
of the parts, latest year
United States37,81139,86341,88442,09743,13340,64041,98146,44450,30253,75257.1%
Europe15,77017,12618,75318,46618,98020,59520,66420,41020,21221,53522.9%
Asia-Pacific, Africa12,57513,42014,83115,55515,13613,57813,23713,75613,59314,03114.9%
Western Hemisphere excluding U.S.5,7346,0416,1135,9415,3353,9274,1084,5494,7144,8755.2%
United StatesEuropeAsia-Pacific, AfricaWestern Hemisphere excluding U.S.
76.5FY201782.1FY201978.7FY202285.2FY202394.2FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Johnson & Johnson's adjusted EPS landed at or above the top of the range in 6, inside it in 3 and under it in 1 of the 10 years shown (FY2010 to FY2019).

−3.8%FY2010+2.0%FY2011−1.0%FY2012+1.3%FY2013+2.1%FY2014−1.1%FY2015+2.3%FY2016+3.1%FY2017−0.2%FY2018+0.3%FY2019
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2010$4.85 to $4.95$4.76
FY2011$4.80 to $4.90$5.00
FY2012$5.05 to $5.15$5.10
FY2013$5.35 to $5.45$5.52
FY2014$5.75 to $5.85$5.97
FY2015$6.12 to $6.27$6.20
FY2016$6.43 to $6.58$6.73
FY2017$6.93 to $7.08$7.30
FY2018$8.00 to $8.20$8.18
FY2019$8.50 to $8.65$8.68
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007FY2008FY2009FY2010FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020FY2021 †FY2022 †FY2023FY2024FY2025TTM
Operating cash flow15,02214,97216,57116,38514,29815,39617,41418,71019,56918,76721,05622,20123,41623,53623,41021,19422,79124,26624,53026,159
Capital expenditure2,9423,0662,3652,3842,8932,9343,5953,7143,4633,2263,2793,6703,4983,3473,6524,0094,5434,4244,8325,569
Free cash flow12,08011,90614,20614,00111,40512,46213,81914,99616,10615,54117,77718,53119,91820,18919,75817,18518,24819,84219,69820,590
Free cash flow margin19.8%18.7%23.0%22.7%17.5%18.5%19.4%20.2%23.0%21.6%23.3%22.7%24.3%24.4%25.1%21.5%21.4%22.3%20.9%20.7%
Cash from investing-5,912-4,187-7,598-7,854-4,612-4,510-5,103-12,305-7,735-4,761-14,868-3,167-6,194-20,825-8,683-12,371878-18,599-23,588-9,344
Cash from financing-5,698-7,464-4,092-4,980-4,452-20,562-6,091-12,499-11,136-8,551-7,673-18,510-18,015-6,120-14,047-8,871-15,825-3,132-5,539-18,149
Depreciation and amortisation2,7772,8322,7742,9393,1583,6664,1043,8953,7463,7545,6426,9297,0097,2317,3906,9707,4867,3397,5038,091
Share-based compensation6986276286146216627287928748789629789771,0051,1351,1381,1621,1761,3541,424
Buybacks5,6076,6512,1302,7972,52512,9193,5387,1245,2908,9796,3585,8686,7463,2213,4566,0355,0542,4325,9537,882
Dividends paid4,6705,0245,3275,8046,1566,6147,2867,7688,1738,6218,9439,4949,91710,48111,03211,68211,77011,82312,38112,716
Dividend per share$1.62$1.79$1.93$2.11$2.25$2.40$2.59$2.76$2.95$3.15$3.32$3.54$3.75$3.98$4.19$4.45$4.70$4.91$5.14n/a
Diluted shares, weighted2,911m2,836m2,789m2,789m2,775m2,813m2,877m2,864m2,813m2,789m2,745m2,729m2,684m2,671m2,674m2,664m2,560m2,429m2,429m2,449m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a2,407m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008FY2009FY2010FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018 †FY2019FY2020FY2021 †FY2022 †FY2023FY2024FY2025TTM
Funded by
Shareholders' equity43,31942,51150,58856,57957,08064,82674,05369,75271,15070,41860,16059,75259,47163,27874,02376,80468,77471,49081,54481,529
Non-controlling interestn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a0.0n/an/an/an/a
Short-term borrowingsn/a3,7326,318n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Debtn/a8,1208,25716,77319,62716,16518,18018,76019,86127,12634,58130,48027,69635,26633,75139,64229,33236,63447,93344,651
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a716n/an/an/an/an/an/an/a
Other liabilitiesn/a30,54929,51929,55636,93740,35640,45041,84642,40043,66462,56262,72269,84576,35074,24470,93269,45271,98069,73371,245
Total liabilities and equityn/a84,91294,682102,908113,644121,347132,683130,358133,411141,208157,303152,954157,728174,894182,018187,378167,558180,104199,210197,425
Owned
Fixed assetsn/a14,36514,75914,55314,73916,09716,71016,12615,90515,91217,00517,03517,65818,76618,96217,98219,89820,51823,16924,104
Goodwilln/a13,71914,86215,29416,13822,42422,79821,83221,62922,80531,90630,45333,63936,39325,43636,04736,55844,20048,77248,474
Intangible assetsn/a13,97616,32316,71618,13828,75227,94727,22225,76426,87653,22847,61147,64353,40246,39238,48934,17537,61850,40346,652
Investmentsn/a2,0453,6158,3037,7196,1788,27918,56624,64422,9354721,5801,98211,20017,1219,3921,068417393318
Cash and equivalents7,77010,76815,81019,35524,54214,91120,92714,52313,73218,97217,82418,10717,30513,98514,48712,88921,85924,10519,70916,910
Receivablesn/a9,7199,6469,77410,58111,30911,71310,98510,73411,69913,49014,09814,48113,57615,28314,03914,87314,84217,17818,987
Inventoryn/a5,0525,1805,3786,2857,4957,8788,1848,0538,1448,7658,5999,0209,34410,38710,26811,18112,44414,19115,377
Other assetsn/a15,26814,48713,53515,50214,18116,43112,92012,95013,86514,61315,47116,00018,22833,95048,27227,94625,96025,39526,603
Total assetsn/a84,91294,682102,908113,644121,347132,683130,358133,411141,208157,303152,954157,728174,894182,018187,378167,558180,104199,210197,425
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded3.0%2.7%5.6%7.8%
Profit growth, compounded5.7%12.7%14.3%-35.9%
Return on equity, average25.5%31.0%34.6%32.9%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Johnson & Johnson's revenue in fiscal 2025?

Johnson & Johnson (JNJ) reported revenue of $94.2 billion for fiscal 2025, the year ended 28 December 2025, up 6.0% on the year before.

How much did Johnson & Johnson earn in fiscal 2025?

Net income was $26.8 billion for fiscal 2025, and diluted earnings per share $11.03.

What is Johnson & Johnson's P/E ratio?

At the close of 6 November 2026, Johnson & Johnson traded at 41.9 times its earnings over the twelve months to 27 September 2026.

What is Johnson & Johnson's market cap?

The market cap of Johnson & Johnson was $665.0 billion at the close of 6 November 2026.

Does Johnson & Johnson pay a dividend?

Yes. Johnson & Johnson declared $5.28 a share in dividends over the four quarters to 27 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on JNJ

Dividends$5.28 a share over the four quarters to 27 September 2026, a 1.91% yield
Filings19 in twelve months: 8 current reports (8-K), about 4 results of operations; 2 regulation FD disclosure; 1 officer or director change; 1 shareholder vote; 1 other events
Planned insider sales17 Form 144 notices in twelve months, $151.9 million; latest 2 September 2026
Options tapeput/call 0.91 by open interest at the 6 November 2026 close; the straddle prices a 3.1% move to 13 November 2026
13F holders4,716 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading28 sales and 1 purchase on Form 4 in twelve months
Congress7 House trades disclosed in six months
Short interest16.8 million shares short, 1.97 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q27 September 202621 October 2026EDGAR
10-Q28 June 202623 July 2026EDGAR
10-Q29 March 202622 April 2026EDGAR
10-K28 December 202511 February 2026EDGAR
10-Q28 September 202522 October 2025EDGAR
10-Q29 June 202524 July 2025EDGAR
10-Q30 March 202523 April 2025EDGAR
10-K29 December 202413 February 2025EDGAR
10-Q29 September 202423 October 2024EDGAR
10-Q30 June 202425 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.